Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer

被引：0

作者：

Govindan, R. ^{[1
]}

Fakih, M. ^{[2
]}

Price, T. ^{[3
]}

Falchook, G. ^{[4
]}

Desai, J. ^{[5
]}

Kuo, J. ^{[6
]}

Strickler, J. ^{[7
]}

Krauss, J. ^{[8
]}

Li, B. ^{[9
]}

Denlinger, C. ^{[10
]}

Durm, G. ^{[11
]}

Ngang, J. ^{[12
]}

Henary, H. ^{[12
]}

Ngarmchamnanrith, G. ^{[12
]}

Rasmussen, E. ^{[12
]}

Morrow, P. K. ^{[12
]}

Hong, D. ^{[13
]}

机构：

[1] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA

[2] City Hope Natl Med Ctr, Duarte, CA USA

[3] Queen Elizabeth Hosp, Woodville South, Australia

[4] HealthONE, Sarah Cannon Res Inst, Denver, CO USA

[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[6] Scientia Clin Res, Randwick, NSW, Australia

[7] Duke Univ, Med Ctr, Durham, NC 27706 USA

[8] Univ Michigan, Ann Arbor, MI 48109 USA

[9] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[10] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[11] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

[12] Amgen Inc, Thousand Oaks, CA 91320 USA

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期

关键词：

AMG; 510; lung cancer; KRAS G12C; NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA01.06

引用

页码：S1125 / S1126

页数：2

共 50 条

[31] NINTEDANIB, A NOVEL TRIPLE ANGIOKINASE INHIBITOR FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
Noonan, S.
Wong, K. Man
Jimeno, A.
DRUGS OF TODAY, 2015, 51 (06) : 357 - 366
[32] Real World Efficacy and Safety of Sotorasib in US Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer
Zhou, K. I.
Lin, C.
Tseng, C. -L.
Ramnath, N.
Dowell, J. E.
Kelley, M. J.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S337 - S338
[33] Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
Cui, Wanyuan
Franchini, Fanny
Alexander, Marliese
Officer, Ann
Wong, Hui-Li
IJzerman, Maarten
Desai, Jayesh
Solomon, Benjamin J.
LUNG CANCER, 2020, 146 : 310 - 317
[34] Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion plus Non-Small Cell Lung Cancer
Zhou, Q.
Wu, Y.
Chang, J.
Wang, H.
Fan, Y.
Zhao, J.
Wu, G.
Sun, Y.
Sun, M.
Wang, X.
Shi, H.
Nian, W.
Wang, K.
Zheng, X.
Qu, L.
Yao, S.
Shen, Z.
Li, P.
Yang, J.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S889 - S890
[35] Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
Shi, Xiaoshun
Dong, Xiaoying
Zhai, Jianxue
Liu, Xiguang
Lu, Di
Ni, Zhen
Wu, Hua
Cai, Kaican
FRONTIERS IN ONCOLOGY, 2021, 11
[36] EVALUATION OF EFFICACY AND SAFETY OF BEVACIZUMAB COMBINED WITH CHEMOTHERAPY FOR CHINESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
Zhong, W.
Zhang, L.
Zhao, J.
Wang, M-Z
Li, L-Y
RESPIROLOGY, 2011, 16 : 146 - 146
[37] Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy
Lan, Shao
Zhang Beibei
He Chunxiao
Lin Baochai
Song Zhengbo
Lou Guangyuan
Yu Xinmin
Zhang Yiping
CHINESE MEDICAL JOURNAL, 2014, 127 (02) : 266 - 271
[38] Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer
Besse, Benjamin
Garrido, Pilar
Cortot, Alexis B.
Johnson, Melissa
Murakami, Haruyasu
Gazzah, Anas
Gil, Maciej
Bennouna, Jaafar
LUNG CANCER, 2020, 142 : 63 - 69
[39] Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer
Peravali, Monica
Ahn, Jaeil
Chen, Kevin
Rao, Suman
Veytsman, Irina
Liu, Stephen V.
Kim, Chul
ONCOLOGIST, 2021, 26 (08) : 694 - 700
[40] Reviewing the safety of erlotinib in non-small cell lung cancer
Reck, Martin
Mok, Tony
Wolf, Juergen
Heigener, David
Wu, Yi-long
EXPERT OPINION ON DRUG SAFETY, 2011, 10 (01) : 147 - 157

← 1 2 3 4 5 →